Education

M.S., Physiology - (8/1998 – 8/2003)

University of Texas Graduate School of Biomedical Sciences

University of Texas Health Science Center at San Antonio, San Antonio, TX

B.S., Zoology, Minor: Chemistry - (9/1994 – 6/1998)

Weber State University

Ogden, Utah

Experience

Teaching Experience

• Supplemental Instruction – Human Biology course – Weber State University
• Physiology Lab Assistant – Weber State University
• Anatomy Lab Instructor – Weber State University
• Teacher Assistant – Medical Physiology – UTHSCSA Medical School
• Experiments in Physiology Lead Teacher Assistant – UTHSCSA Medical School
• Adjunct Faculty San Antonio College – Anatomy & Physiology Course

Publications

1. Pratipanawatr, W; Pratipanawatr, T; Cusi, K; Berria, R; Adams, J+; Jenkinson, CP; Maezono, K; DeFronzo, RA; Mandarino, LJ: Skeletal Muscle Insulin Resistance in Normoglycemic Subjects With A Strong Family History of Type 2 Diabetes Is Associated With Decreased Insulin-Stimulated Insulin Receptor Substrate-1 Tyrosine Phosphorylation. Diabetes 50:2572-2578, 2001
2. Pratipanawatr, W; Pratipanawatr, T; Cusi, K; Berria, R; Adams, J; Christ, CY; Jenkinson, CP; DeFronzo, RA; Mandarino, LJ: Insulin-Stimulated Insulin Receptor Substrate-1 (IRS-1) Tyrosine Phosphorylation is Decreased in Normal Glucose Tolerant Subjects with a Strong Family History of Type 2 Diabetes Mellitus. Diabetes 50:A315, 2001
3. Adams, J; Pratipanawatr, T; Mandarino, LJ: Kinetics of Akt Activation by Insulin in Human Skeletal Muscle. Diabetes 51 A571, 2002
4. Adams, J: Regulation of Akt Serine 473 Phosphorylation by Insulin in Skeletal Muscle of Obese Nondiabetic Humans: Consequence of Lipid Oversupply. Master's Thesis, May 2003
5. Adams, J; Pratipanawatr, T, Berria, R; Wang, E; DeFronzo, RA; Sullards, MC; Mandarino, LJ: Ceramide Content Is Increased in Skeletal Muscle from Obese Insulin-Resistant Humans. Diabetes 53:25-31, 2004
6. Solis-Herrera, C; Triplitt, C; Garduno-Garcia, J; Adams, J; DeFronzo, R; Cersosimo, E: Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. Diabetes Care. 2013 Sep; 36(9):2756-62.
7. Abdul-Ghani, MA; Puckett, C; Triplitt, C; Maggs, D; Adams, J; Cersosimo, E; DeFronzo, RA: Initial Combination Therapy with Metformin, Pioglitazone and Exenatide is More Effective than Sequential Add-on Therapy in Subjects With New-Onset Diabetes. Results From the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): A Randomized Trial. Diabetes, Obesity, and Metabolism 17 268-275, March 2015.
8. Eldor, R; Daniele, G; Huerta, C; Al-Atrach, M; Adams, J; DeFronzo, R; Duong, T; Lancaster, J; Zirie, M; Jayyousi, A; Abdul-Ghani, M: Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects. Diabetes Care. 2016 Oct:39(10):1804-1810.
9. Abdul-Ghani, M; Migahid, O; Megahed, A; Adams, J; Triplitt, C; DeFronzo, RA; Zirie, M; Jayyousi, A: Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Poorly Controlled Patients With Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care. 2017 Jun. 40:325-331.
10. Al Jobori, H; Daniele, G; Adams, J; Cersosimo, E; Triplitt, C; DeFronzo, RA; Abdul-Ghani, M: Determinants of the Increase in Fasting Plasma Ketone Concentration during SGLT2 Inhibition in NGT, IFG and T2DM Patients. Diabetes Obes metab. 2017 Jun; 19(6):809-813
11. Alatrach, M; Agyin, C; Adams, J; DeFronzo, RA; Abdul-Ghani, MA: Decreased Basal Hepatic Glucose Uptake in Impaired Fasting Glucose. Diabetologia. 2017 Jul; 60(7):1325-1332
12. Abdul-ghani, M; Migahid, O; Megahed, A; Adams, J; Triplitt, C; DeFronzo, RA; Zirie, M; Jayyousi, A: Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017 Aug; 40(8):1134
13. Abdul-Ghani, M; Al Jobori, H; Daniele, G; Adams, J; Cersosimo, E; Triplitt, C; DeFronzo, RA: Inhibition of Renal Sodium-glucose Cotransport with Empagliflozin Lowers Fasting Plasma Glucose and Improves Beta-Cell function in Subjects With Impaired Fasting Glucose. Diabetes 2017 Sep; 66(9): 2495-2502.
14. Al Jobori, H; Daniele G, Adams, J; Cersosimo, E; Solis-Herrera, C; Triplitt, C; DeFronzo, RA; Abdul-Ghani, M: Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM. Journal of Clinical Endocrinology and Metabolism. 2018 Apr 1; 103(4): 1402-1407.
15. Martinez, R; Al Jobori, H; Ali, AM; Adams, J; Abdul-Ghani, M; Triplitt, C; DeFronzo, RA; Cersosimo, E: Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. Diabetes. 2018 Jun; 67(6):1182-1189.
16. Alatrach, M; Agyn, C; Adams, J; Chilton, R; Triplitt, C; DeFronzo, RA; Cersosimo, E: Glucose Losering and Vascular Protective Effects of Cycloset Added to GLP-1 Receptor Agonists in Patients with Type 2 Diabetes. Endocrinology Diabetes Metab. 2018 Aug 15; 1(4):e00034.
17. Alatrach, M; Agyin, C; Mehta, R; Adams, J; DeFronzo, RA; Abdul-Ghani, M: Glucose-Mediated Glucose Disposal at Baseline Insulin is Impaired in IFG. J Clin Endocrinol Metab. 2019 Jan 1; 104(1):163-171.
18. Binda, P; Eldor, R; Huerta, C; Adams, J; Lancaster, J; Fox, P; Del Prato, S; DeFronzo, R; Abdul-Ghani, M; Daniele, G: Exenatide Modulates Visual Cortex Responses. Diabetes/Metabolism Res Rev. 2019 Apr 11:e3167
19. Norton, L; Fourcaudot, M; Adams, J; Triplitt, C; Puckett, C; Abdul-Ghani, M; Cersosimo, E; DeFronzo, R: FGF21 Contirbutes to Metabolic Improvements Elicited by Exenatide and Pioglitazone in Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2019 In Submission